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A bstract
Background: Regulatory T cell (Treg) based immunotherapy is a potential treatment for several immune disorders. By now, 
this approach proved successful in preclinical animal transplantation and auto-immunity models. In these models the 
success of Treg based immunotherapy crucially depends on the antigen-specificity of the infused Treg population. For the 
human setting, information is lacking on how to generate Treg with direct antigen-specificity ex vivo to be used for 
immunotherapy.
M ethodology/Principal Findings: Here, we demonstrate that in as little as two stimulation cycles with HLA mismatched 
allogeneic stimulator cells and T cell growth factors a very high degree of alloantigen-specificity was reached in magnetic 
bead isolated human CD4posCD25high Treg. Efficient increases in cell numbers were obtained. Primary allogeneic stimulation 
appeared a prerequisite in the generation of alloantigen-specific Treg, while secondary allogeneic or polyclonal stimulation 
with anti-CD3 plus anti-CD28 monoclonal antibodies enriched alloantigen-specificity and cell yield to a similar extent.
Conclusions/Significance: The ex vivo expansion protocol that we describe will very likely increase the success of clinical 
Treg-based immunotherapy, and will help to induce tolerance to selected antigens, while minimizing general immune 
suppression. This approach is of particular interest for recipients of HLA mismatched transplants.
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Introduction
Regulatory T cells (Treg) play a critical role in various 
immunological processes. These cells dampen immune responses, 
which is important in maintenance of (self-) tolerance and 
homeostasis. Immunotherapy based on Treg (either in vivo 
facilitation of Treg or infusion of ex vivo isolated /  manipulated 
Treg) is therefore a potential treatment for many immune 
disorders. Such an approach has been proven successful in animal 
models of stem cell transplantation [1—7], solid organ transplan­
tation [8,9], auto-immunity [10-14] and even in infertility [15]. 
Treg therapy in human patients will require high cell numbers, 
which might be obtained by ex vivo expansion. It has been shown 
that human naturally occurring CD4posCD25high Treg can be 
expanded polyclonally, by using anti-CD3 and anti-CD28 
antibody stimulation in combination with IL-2 and/or IL-15 
[16-21]. These polyclonal expansion protocols greatly increase 
Treg numbers, while preserving suppressive capacity. However, 
there are some drawbacks regarding clinical application of 
polyclonally expanded Treg. First, since this type of activation 
encompasses Treg with a broad range of specificities, the infused 
polyclonal Treg may suppress immune responses other than the
target response, thereby increasing the risk for opportunistic 
infections and tumor-growth. Second, due to the low percentage of 
Treg within a polyclonal cell pool that is specific for a given target 
antigen, large numbers of Treg need to be infused. These 
difficulties could be overcome by using antigen-specific Treg. In 
animal models, antigen-specific Treg have been shown to be far 
more efficient than polyclonal Treg [4,6,7,12-14]. Even as few as 
5 x 103 antigen-specific Treg were sufficient to prevent the onset of 
diabetes in a NOD model [14].
For the human setting, information is scarce on how to generate 
sufficient numbers of antigen-specific Treg ex-vivo from naturally 
occurring Treg [22]. The aim of this study was to design a 
successful strategy to obtain high numbers of Treg with direct 
alloantigen-specificity for use in transplantation settings. Based on 
previous findings, we hypothesized that it would be beneficial to 
combine polyclonal stimulation, to boost expansion, with alloan­
tigen stimulation, to increase antigen-specificity. To test this 
hypothesis, we alternated these two stimulation methods in 
primary and secondary Treg expansion cycles and assessed cell 
numbers, phenotype, function and antigen-specificity before and 
after expansion. Thus, we succeeded in defining a protocol that 
yields high numbers of strictly alloantigen-specific human Treg.
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Results
Optimal conditions for primary and secondary expansion 
cycles
With the objective to obtain the highest numbers of functionally 
active Treg with optimal direct alloantigen-specificity, we devised 
four expansion strategies, employing polyclonal and alloantigen- 
specific stimulation in two subsequent cycles of Treg expansion 
(Figure 1). The cells that were obtained with these expansion 
strategies were compared in terms of absolute cell numbers, 
phenotype, suppressive capacity, antigen-specificity and anergy. 
Prior to analysis of the four selected Treg expansion strategies, 
individual expansion cycles were optimized, with regard to 
strength and mode of stimulation.
Cell sorting based on multiple surface markers such as CD25, 
CD127, CD62L and CD27 yields a high purity of FoxP3pos Treg. 
However, these tools are not available for clinical grade purposes. 
Therefore, we specifically chose to use magnetic bead isolation 
for purification of Treg, as this most closely fits with the 
currently available GMP isolation tools. Cells isolated by this 
procedure expressed CD25 and FoxP3, but not CD127 
(Figure 2A), thus displaying a typical Treg phenotype [23-26]. 
In contrast, CD4posCD25neg conventional T cells (Tconv) did not 
express FoxP3 or CD25, and were positive for CD127. The 
majority of the isolated Treg as well as Tconv expressed the 
differentiation marker CD27, not its ligand CD70, and were 
positive for CD62L.
The freshly isolated Treg were hyporesponsive upon restimu­
lation (Figure 2B) and able to suppress proliferation of autologous 
CD4posCD25neg T cells upon stimulation with alloantigen 
(Figure 2C, D and E), >50% suppression was seen with 
Tresp:Treg ratios of 4:1 or lower (Figure 2C). Tconv were not 
anergic, nor suppressive.
For alloantigen driven expansion, the optimal strength of 
alloantigen stimulation was determined by titrating irradiated 
HLA mismatched allogeneic PBMC into Treg cultures, in the 
presence of exogenous IL-2 and IL-15. In a primary MLR, 
proliferation was maximal with stimulator:responder ratios of 4:1 
(Figure 3A). Secondary stimulation with alloantigen showed 
similar results (Figure 3B). The data shown in Figure 3B were 
obtained with Treg primed with alloantigen, but similar results 
were observed when polyclonally primed Treg were used (data not 
shown). Consequently, for expansion experiments, a stimulator:- 
responder ratio of 4:1 was used. Interestingly, a higher number of 
HLA-DRB1 mismatches between stimulator and responder 
resulted in higher expansion rates (P<0.05) (Figure 3C). Mis­
matches at other HLA genes did not significantly correlate with 
expansion efficiency (data not shown).
For polyclonal stimulation we used CD3 and CD28 triggering, 
and we compared anti-CD3+ anti-CD28 mAb coated microbeads 
with platebound anti-CD3+ soluble anti-CD28 mAb stimulation. 
For primary expansion of Treg, higher proliferation rates were 
achieved with beads as compared to platebound anti-CD3+ 
soluble anti-CD28 mAb (Figure 4A). Cell yield after expansion of 
Treg with either stimulation mode, using optimal dosage, was 
higher for anti-CD3+ anti-CD28 bead stimulation as compared to 
platebound anti-CD3+ soluble anti-CD28 stimulation (Figure 4B). 
To explain these differences, we assessed cell division and survival 
in Treg cultures for both stimuli (Figure 4C). Upon stimulation 
with anti-CD3+ anti-CD28 mAb coated beads, the majority of cells 
were triggered to proliferate as determined by CFSE dilution. 
Expression of 7AAD, a marker for late apoptotic cells, was low. Bcl-
2, an anti-apoptotic protein, was expressed by 70-85% of the cells. 
Further gating revealed that the dividing cell population specifically 
expressed Bcl-2. Upon stimulation with platebound anti-CD3+ 
soluble anti-CD28 mAb, and independent of the concentration 
used, a large portion of cells was not triggered to proliferate. Again 
7AAD staining was low. The percentage of cells that expressed Bcl-2 
was lower as compared to cells stimulated with anti-CD3+ anti- 
CD28 beads, this correlated with the percentage of dividing cells. 
The results indicate that the lower cell yield after stimulation of Treg 
with platebound anti-CD3+ soluble anti-CD28 mAb is merely 
caused by less efficient triggering of Treg proliferation, and is not the 
result of enhanced cell death.
These experiments were also conducted for secondary poly­
clonal stimulation. In this situation, platebound anti-CD3+ soluble 
anti-CD28 stimulation was superior as a secondary stimulus as 
compared to anti-CD3+ anti-CD28 microbead stimulation 
(Figure 5A). Expansion cultures stimulated with platebound anti- 
CD3+ soluble anti-CD28 yielded more Treg as compared to 
cultures stimulated with anti-CD3+ anti-CD28 beads (Figure 5B). 
Attempting to explain these findings, we again assessed cell 
division and survival in Treg cultures using both stimuli 
(Figure 5C). In contrast to the results after primary stimulation, 
both polyclonal stimuli now induced massive proliferation as 
assessed by CFSE dilution. Also, both 7AAD staining and Bcl-2 
expression were comparable between Treg cultures stimulated 
with either anti-CD3+ anti-CD28 beads or platebound anti-CD3+ 
soluble anti-CD28 mAb. The data shown in Figure 5 were 
obtained with Treg primed with anti-CD3+ anti-CD28 beads, 
similar results were observed when alloantigen primed Treg were 
used (data not shown). Overall, these data prompted us to use
Treg isolation
I
Cycle 1
Cycle 2
Alloantigen Polyclonal
stimulation stimulation
Alloantigen Polyclonal Alloantigen Polyclonal
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Figure 1. Schem atic overview  o f expansion  strateg ies. Treg were expanded in two cycles, in which alloantigen and polyclonal stimulation was 
alternated, resulting in four distinct strategies: two subsequent cycles with alloantigen stimulation; primary cycle with alloantigen stimulus and 
secondary cycle with polyclonal stimulus; primary cycle with polyclonal stimulus and secondary cycle with alloantigen stimulus; and two subsequent 
cycles with polyclonal stimulation. 
doi:10.1371/journal.pone.0002233.g001
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Figure 2. Phenotypical and functional characteristics o f freshly  
MACS-isolated Treg. CD4pos T cells were negatively isolated from 
PBMC and separated into CD25pos (Treg) and CD25neg (Tconv) T cell 
fractions by magnetic cell sorting. Data from a typical isolation is 
shown. (A) Cell surface expression of CD25, CD127, CD27, CD70 and 
CD62L, and intracellular expression of FoxP3 were analyzed on Treg 
(blackfilled histograms) or Tconv (grey line histogram). (B) Proliferative 
capacity of Treg or Tconv upon stimulation with HLA mismatched 
gamma irradiated allogeneic PBMC was determined in the absence 
(black bar) or presence (grey bar) of exogenous IL-2. Proliferation was 
determined by measuring [3H]Thymidine incorporation at day 5. (C) 
Suppressive capacity of Treg in alloantigen responses was determined 
in a MLR co-culture using [3H]Thymidine incorporation. Autologous 
naive CD4posCD25neg Tresp cells were stimulated with HLA mismatched 
gamma irradiated allogeneic PBMC. Treg (black lines) or Tconv (grey 
lines) were added into these cultures at indicated Tresp:Treg/Tconv
ratios. Proliferation was determined by measuring [ H]Thymidine 
incorporation at day 5. Results are expressed as percentage of 
[3H]Thymidine incorporation +SD, indexed to [3H]Thymidine incorpora­
tion of naive Tresp and antigen only. (D) Suppressive capacity of Treg in 
alloantigen responses was determined in a MLR co-culture using CFSE 
dilution. CFSE labeled autologous naive CD4posCD25neg Tresp cells were 
stimulated with PKH26 labeled HLA mismatched gamma irradiated 
allogeneic PBMC. Treg (black lines) or Tconv (grey lines) were added 
into these cultures at indicated Tresp:Treg/Tconv ratios. Proliferation 
was determined by measuring CFSE dilution of Tresp at day 5. Results 
are expressed as percentage of proliferating cells, indexed to 
percentages of proliferating cells in cultures of naive Tresp and antigen 
only. (E) Example CFSE of suppression assay as described in Figure 2D. 
Tresp only (grey filled histogram), Tresp+Treg (1:1, black line) and 
Tresp+Tconv (1:1, grey line) are shown, numbers indicate percentage of 
proliferating cells, indexed to percentages of proliferating cells in 
cultures of naive Tresp and antigen only. 
doi:10.1371/journal.pone.0002233.g002
platebound CD3+ soluble CD28 mAb for polyclonal Treg 
restimulation in further experiments.
Several reports have described the use of high dose IL-2 in Treg 
expansion protocols [16,17]. Our laboratory and others have 
shown that combination of IL-2 and IL-15 increases Treg 
proliferation [21,27]. We thus added titrated concentrations of 
IL-2 (range 12,5 U /m l to 200 U/ml) with a fixed concentration of 
IL-15 (10 ng/ml) to Treg cultures to determine the optimal IL-2 
dose in our system. Concentrations of 25 U /m l or higher gave 
similar results in terms of Treg yield (data not shown). We 
therefore chose to use 25 U /m l IL-2 in combination with 10 ng/ 
ml IL-15 for expansion experiments.
To determine the optimal cycle length, cell numbers were 
counted at several time points during primary and secondary 
expansion cycles. Expansion values were calculated and are 
depicted in Figure 6. In primary Treg expansion cycles with either 
alloantigen or polyclonal stimulation, cultures reached maximal 
cell numbers after 10-12 days. In secondary expansion cycles with 
alloantigen stimulation, peak cell numbers were found at day 10. 
In secondary expansion cycles with polyclonal stimulation, peak 
cell numbers were found at day 10 if cells had been primed with 
alloantigen. However, when Treg had been primed with 
polyclonal stimulation, a plateau in cell numbers in a secondary 
polyclonal stimulation cycle was reached around day 7. Since our 
prime interest was to obtain alloantigen-specific Treg, the strategy 
comprising two subsequent cycles with polyclonal stimulation 
actually served as a control. Consequently, we standardized the 
expansion cycle length at 10 days for all strategies.
Cell yield after Treg expansion with combined 
alloantigen and polyclonal stimulation strategies
Having optimized the conditions for the primary and secondary 
expansion cycles, we now isolated Treg and Tconv and 
subsequently applied multiple expansion cycles according to the 
strategies depicted in Figure 1. Average Treg expansion values are 
shown in Figure 7. Contrary to our expectation that stimulation 
cycles with alloantigen would provide lower cell yields as 
compared to cycles of polyclonal expansion, Treg numbers 
obtained after each of the four expansion strategies were similar 
(average fold expansion 780, SD 300, p = 0.71, N = 4).
Phenotypic characterization of expanded Treg
A potential risk of Treg expansion is the outgrowth of 
contaminating cell types such as CD8pos T cells or NK-cells. In 
our experiments, we did not find major contaminations, since 
typically >90% of the expanded cells were CD4pos T cells. The
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Figure 3. D eterm ination of optim al strength  of alloantigen  Treg stim ulation. (A) Treg were stimulated with indicated ratios of irradiated 
allogeneic PBMC in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [3H]Thymidine incorporation at day 5. Data are 
representative of three independent experiments. (B) Treg primed with alloantigen were restimulated with indicated ratios of irradiated allogeneic 
PBMC in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [3H]Thymidine incorporation at day 3. Data are 
representative of three independent experiments. (C) Efficiency of primary alloantigen stimulated expansion is related to the number of HLA-DRB1 
mismatches. Freshly isolated Treg were expanded in one cycle in the presence of IL-2 and IL-15 and stimulation by gamma irradiated allogeneic 
PBMC with one (N = 10) or two (N = 6) mismatches on HLA class II DRB1 genes. Expansion values were calculated by relating the number of cells set 
up in the initial culture to the number of cells after expansion (after two days rest). Expansion was higher with alloantigen mismatched on two HLA- 
DRB1 genes as compared to alloantigen with one mismatch. This difference was found to be statistically significant in a Mann Whitney test (P = 0.025). 
doi:10.1371/journal.pone.0002233.g003
majority of Treg expanded with either strategy was CD25high, and 
CD127neg (Figure 8). The majority of Treg retained expression of 
FoxP3pos after two cycles of expansion. Tconv cells were largely 
FoxP3neg. Previously, we and others have shown that Treg 
constitutively expressing CD27 are stronger suppressors [17,27]. 
Typically, after expansion, a portion of Treg retained a CD27pos 
phenotype, while the remaining Treg shifted towards a CD27neg 
phenotype. Treg expanded with two cycles of polyclonal 
stimulation repeatedly showed the highest percentage of CD27pos 
cells (50 to 80%), while cells expanded with two subsequent 
alloantigen stimulation cycles had the lowest percentage of 
CD27pos cells (10 to 40%). The two strategies with alternated 
alloantigen and polyclonal stimulation cycles showed intermediate 
percentages of CD27pos cells. The expression of CD70, the ligand 
for CD27, was reversely correlated with CD27 expression. CD62L 
is also described as a marker for Treg with high suppressive 
potency [24]. Whereas expression of CD62L was lost on expanded 
Tconv cells, a substantial portion of Treg retained expression of 
this marker.
Functional characterization of expanded Treg
Treg retain anergic properties after expansion. One of
the hallmarks of Treg is their anergic (hyporesponsive) behavior in 
vitro. Treg retained their anergic state after expansion, irrespective 
of the strategy employed, while in contrast Tconv were not 
anergic. Indeed, Treg did not proliferate upon stimulation in 
absence of exogenous T cell growth factors, while addition of IL-2 
restored the proliferative capacity (Figure 9).
Expanded Treg show enhanced suppressive capacity and 
can acquire full antigen-specificity within two expansion 
cycles. The main characteristics of alloantigen-specific Treg 
should be their strong suppressive capacity when stimulated by 
target antigen (in transplantation settings this would be donor 
antigen), in parallel with a lack of suppressive activity in the case of 
stimulation by other antigens such as fully HLA mismatched third 
party alloantigen. To assess suppressive capacity, we used both the 
classic [3H]Thymidine incorporation co-culture suppression assay
as well as a CFSE based assay. The latter is used because in some 
instances it is difficult to draw clear conclusions from the 
[3H]Thymidine assay when using multiple cell populations.
Figure 10 shows that highly antigen-specific Treg were obtained 
in two situations. Treg expanded with two cycles of alloantigen 
stimulation showed very high suppressive activity in target antigen 
driven MLR (>90% suppression in all ratios tested, Figure 10A) 
and hardly any suppression of third party antigen driven MLR. 
The cells obtained after the strategy starting off with a primary 
allostimulation, followed by secondary polyclonal stimulation, also 
yielded potent Treg with high antigen-specificity, as indicated by 
strong suppression of target antigen driven responses (>50% 
suppression with Tresp:Treg ratios of 16:1 or lower, Figure 10A) 
and low inhibition of third party HLA mismatched allostimulated 
MLR. Importantly, these data show that under these circum­
stances a very high degree of antigen-specificity can already be 
obtained after two cycles of expansion. This is relevant since we 
have noticed that multiple expansion cycles, irrespective of the 
mode of stimulation, can lead to reduced suppressive capacity, cell 
exhaustion, and subsequent cell death (data not shown). The 
expansion strategy starting off with a primary polyclonal stimulus 
followed by a secondary alloantigen stimulus yielded very potent 
suppressors, showing >90% suppression of target antigen driven 
MLC at all ratios tested (highest ratio tested 32:1, Figure 10A). 
However, this cell population was still capable of suppression in 
third party alloantigen driven responses, albeit at a much lower 
efficiency than target antigen driven responses (>50% suppression 
at Tresp:Treg ratios 2:1 or lower, Figure 10A), indicating a strong 
enrichment Treg specific for target antigen, but incomplete 
exclusion of Treg with other specificities. As expected, Treg 
expanded with two cycles of polyclonal stimulation showed 
suppression of both target antigen as well as 3rd party alloantigen 
driven MLR to a similar, moderate degree (>50% suppression at 
8:1 and 4:1 or lower, respectively, Figure 10A). Treg displayed 
similar suppressive activity in CFSE suppression assays, while 
expanded Tconv were not suppressive (Figure 10B). Note that in 
the [3H]Thymidine based suppression assays (Figure 10A), the low
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Figure 4. Determ ination o f optim al m ode and strength  o f primary polyclonal Treg stim ulation. (A) Treg were stimulated with indicated 
ratios of anti-CD3+ anti-CD28 microbeads or with indicated concentrations of platebound anti-CD3+ soluble anti-CD28 (1 mg/ml) in the presence of 
IL-2 and IL-15. Proliferation was determined by measurement of [3H]Thymidine incorporation at day 4. (B) Indexed cell yield after primary polyclonal 
Treg culture using optimal strength of anti-CD3+ anti-CD28 microbeads (set to 100%) or platebound anti-CD3 plus soluble anti-CD28 stimulation. (C) 
Cell division pattern and survival/death signals of Treg after different primary polyclonal stimulations. Treg were stained with CFSE and stimulated 
with optimal strength of anti-CD3+ anti-CD28 microbeads or platebound anti-CD3+ soluble anti-CD28. CFSE dilution pattern, 7AAD staining and Bcl-2 
expression of Treg population were assessed at day 4. In the lowest row, Bcl-2 expression is depicted gated on dividing Treg only. Data are 
representative of four independent experiments. 
doi:10.1371/journal.pone.0002233.g004
counts observed after titration of high numbers of expanded 
Tconv are not indicative of suppression per se, but rather a result 
of the very early proliferation of already primed Tconv cells in the 
co-culture. These cells heavily compete for medium components 
with the naive Tresp cells that respond later in time. Tconv 
present in substantial numbers may indeed lead to distinct culture 
kinetics with an earlier proliferation peak and a net result of lower 
counts at day 5.
In summary, optimal results were obtained with Treg expansion 
in two subsequent cycles of alloantigen stimulation: efficient 
increases in cell numbers, yielding highly potent and strictly 
antigen-specific Treg. The success of Treg expansion with 
alternated alloantigen and polyclonal stimulation depends on the 
order of the stimulation cycles. When Treg are expanded by a 
primary alloantigen stimulus followed by a secondary polyclonal 
stimulus, cells expand efficiently and show highly potent, strictly 
antigen-specific suppressive capacity. The reverse strategy with a 
primary polyclonal stimulus and a secondary alloantigen stimulus, 
yield high numbers of cells, and enrichment for target antigen- 
specific Treg. However, Treg specific for other antigens are still 
present. As expected, two cycles of polyclonal stimulation yielded 
high numbers of Treg. These cells were suppressive, but no 
enrichment for alloantigen-specific Treg had taken place.
D iscussion
High numbers of Treg will be needed for effective Treg 
immunotherapy in humans to facilitate tolerance in patients with 
auto-immunity or after transplantation. Ex vivo Treg expansion 
can provide the solution to obtain these high numbers. 
Therapeutic efficiency can be improved by selecting for target­
antigen reactive Treg, as indicated by preclinical mouse models 
designed to study the prevention of autoimmunity [12-14] and 
graft-versus-host disease [4,6,7]. At the same time, exclusion of 
Treg with specificities for other antigens lowers the risk for 
unwanted non-specific immune suppression, thus decreasing the 
risk on opportunistic infections and tumor growth.
Information on strategies for large scale antigen-specific 
expansion of human Treg is scant [22], as previous studies on ex 
vivo Treg expansion have primarily focused on polyclonal 
stimulation of Treg [16-21]. In the current report, we demonstrate 
the ex vivo generation of Treg with direct alloantigen-specificity 
from human naturally occurring CD4posCD25high Treg in as little 
as two stimulation cycles, requiring primary stimulation with 
HLA-mismatched allogeneic stimulator cells and IL-2 plus IL-15. 
Experiments were performed with alternating allogeneic and 
polyclonal (anti-CD3 anti-CD28 mAb) stimulation to define the ex 
vivo conditions resulting in optimal enrichment of alloantigen- 
specific Treg and high cell yield.
Naturally occurring CD4posCD25high Treg display a polyclonal 
TCR V-beta pattern [28]. Stimulation of this polyclonal Treg 
population with allogeneic stimulator APC has been shown to 
specifically activate alloantigen-reactive Treg in mice [1,4,6,7,29,30] 
and humans [27]. Thus, these studies indicate that it is feasible to 
generate alloantigen-specific Treg from the naturally occurring
CD4posCD25high Treg population. Here, we elaborated on these 
findings and questioned how to generate high numbers of 
alloantigen-specific Treg starting with polyclonal CD4posCD25high 
Treg populations obtained from peripheral blood. We specifically 
focused on a magnetic bead based method for Treg isolation, so as to 
fit in with currently available clinical grade isolation tools, with the 
objective to facilitate easy translation into clinical practice. Clinical 
grade (Good Manufacturing Practice, GMP) CD4posCD25high Treg 
isolation by a magnetic bead based method is now feasible using the 
CliniMACS system [31,32], albeit that Treg purity is suboptimal 
(50-60%). Our recent data on expansion of CliniMACS isolated 
Treg confirms that the results reported here can indeed be 
extrapolated to clinical grade purification (unpublished observa­
tions). Clearly, with regard to purity of the starting population 
magnetic bead isolation is inferior to FACS sorting, but this latter 
method is not readily available for GMP purposes. We obtained with 
high purity FACS sorted Treg similar results regarding antigen 
specificity, but with lower expansion rates and higher overall 
suppressive capacity (unpublished observations).
To design a successful strategy for obtaining high numbers of 
alloantigen-specific Treg, we hypothesized that it might be 
beneficial to combine ex vivo expansion cycles applying polyclonal 
stimulation, to boost expansion, and cycles applying alloantigen 
stimulation, to selectively stimulate alloantigen-specific Treg. Our 
data show that a high degree of alloantigen-specificity could be 
obtained in as little as two cycles of expansion. To increase 
alloantigen-specificity even more, it would be an option to repeat 
alloantigen expansion stimulation for multiple cycles, which in 
theory would progressively enrich for strictly antigen-specific Treg. 
However, if Treg populations were expanded for more than two 
expansion cycles, we observed a loss of suppressive capacity and 
high cell death (unpublished results).
Although highest cell yields were expected after expansion with 
two polyclonal stimulation cycles, our data showed similar cell 
numbers for all strategies. This result may in part be due to the fact 
that we opted for a standardized 10 day culture cycle. This choice 
was made based on the fact that strategies comprising one or more 
alloantigen stimulation cycles showed optimal expansion at day
10. However, expansion of cells in a second subsequent polyclonal 
stimulation cycle reached an optimum at day 7, cell death 
occurred thereafter.
Of note, the strategies described in this report generate Treg 
with direct alloantigen-specificity. These cells may be especially of 
benefit for patients receiving an HLA mismatched stem cell graft, 
where this route of alloantigen-reactivity is important in graft 
versus host pathology [33]. Although transplantation centers 
pursue a high degree of HLA-matching to prevent harmful 
reactions, HLA-locus mismatched and haploidentical transplants 
are increasingly being performed [34]. In these cases current 
immunosuppressive regimen may benefit from the addition of an 
antigen-specific component. In solid organ transplantation, next to 
direct alloantigen recognition, the indirect route of alloantigen 
presentation clearly contributes to graft rejection [35]. With this in 
mind, it was recently shown, that it is also feasible to obtain Treg
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Figure 5. Determ ination o f optim al m ode and strength  o f secondary polyclonal Treg stim ulation. (A) Treg were primed with anti-CD3+ 
anti-CD28 microbeads and restimulated with indicated ratios of anti-CD3+ anti-CD28 microbeads or with indicated concentrations of platebound 
anti-CD3+ soluble anti-CD28 in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [3H]Thymidine incorporation at day 3. 
(B) Indexed cell yield after secondary polyclonal Treg culture using optimal strength of anti-CD3+ anti-CD28 microbeads (set to 100%) or platebound 
anti-CD3+ soluble anti-CD28 stimulation. (C) Cell division pattern and survival/death signals of Treg after different secondary polyclonal stimulations. 
Treg were stained with CFSE and stimulated with optimal strength of anti-CD3+ anti-CD28 microbeads or platebound anti-CD3+ soluble anti-CD28. 
CFSE dilution pattern, 7AAD staining and Bcl-2 expression of Treg population were assessed at day 4. Data are representative of four independent 
experiments.
doi:10.1371/journal.pone.0002233.g005
with indirect alloantigen-specificity by stimulation with autologous 
dendritic cells pulsed with allo-HLA-peptides [36].
Recently, the first clinical trials on Treg immunotherapy have 
been initiated; in these studies, either CliniMACS isolated
CD4posCD25high Treg or ex vivo manipulated CD4pos T cell lines 
containing induced regulatory Tr1 cells are being infused in 
patients receiving stem cell transplantations [22]. So far, no effects 
have been reported.
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Figure 6. Determ ination of optim al length o f primary and secondary Treg expansion cycles. (A) Optimal length of primary Treg expansion 
cycles. Treg were stimulated with CFSE-labeled alloantigen (solid line, solid circle) or polyclonal (dotted line, open circle) stimulus in the presence of IL-2 
and IL-15. At indicated time points, Treg numbers were counted by FACS (excluding CFSEpos allogeneic stimulator cells) and related to Treg numbers at 
initial set up. (B) Optimal length of secondary Treg expansion cycles.Treg were primed with alloantigen (solid lines) or polyclonal (dotted lines) stimulation 
as indicated in the presence of IL-2 and IL-15 and rested for 2 days prior to restimulation. Cells were restimulated with CFSE-labeled alloantigen (solid 
circles) or polyclonal stimulus (open circles) in the presence of IL-2 and IL-15. At indicated time points, Treg numbers were counted by FACS (excluding 
CFSEpos allogeneic stimulator cells) and related to Treg numbers at initial set up. Data are representative of three independent experiments. 
doi:10.1371/journal.pone.0002233.g006
Figure 7. Treg expansion  after primary and secondary cycles w ith alternated alloantigen  or polyclonal stim ulation. Treg and Tconv 
were expanded according the schedule in Figure 1 and rested for two days. Treg numbers were determined and related to Treg numbers at initial set 
up. Data represent average expansion +SD of seven independent experiments. 
doi:10.1371/journal.pone.0002233.g007
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Figure 8. Phenotypical characterization of expand ed  Treg. Treg and Tconv were expanded according the schedule in Figure 1 and rested for 
two days. Cell surface expression of CD25, CD127, CD27, CD70 and CD62L, and intracellular expression of FoxP3 was analyzed on Treg (black filled 
histograms) or Tconv (grey line histogram). Data are representative of four to seven independent experiments. 
doi:10.1371/journal.pone.0002233.g008
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In summary, this study has shown that it is feasible to obtain 
human functional alloantigen-specific Treg in large numbers for 
immunotherapeutic purposes. This may be a valuable aid in the 
clinical application of Treg, aiming at clinical tolerance to selected 
antigens, while minimizing general immune suppression.
M aterials and M ethods
Treg expansion strategies
To determine the optimal expansion strategy for obtaining high 
numbers of functionally active human alloantigen-specific Treg 
from CD4posCD25high Treg, we devised four different strategies, 
consisting of two subsequent cycles of expansion with alternated 
polyclonal and alloantigen-specific stimulation (Figure 1).
Cell preparation / isolation
Buffy coats were purchased from Sanquin bloodbank, Nijmegen, 
The Netherlands. These buffy coats were obtained from healthy 
human donors upon written informed consent with regard to 
scientific use.
The current study did not require approval from an ethical 
committee according to the Dutch Medical Research Involving 
Human Subjects Act (WMO). PBMC were isolated by density 
gradient centrifugation (Lymphoprep, Nycomed Pharma, Ros- 
kilde, Denmark). CD4pos T cells were negatively selected using 
mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16 
(3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) (all 
from BD Biosciences, SanJose, CA), and CD56 (MOC-1) (Dako, 
Glostrup, Denmark) combined with sheep-anti-mouse-IgG coated 
magnetic beads (Dynal Biotech, Oslo, Norway), routinely resulting 
in a >90% pure CD4pos T cell fraction. CD25high Treg and 
CD25neg conventional T cells were separated by MACS-sorting, 
using 10 ml anti-CD25 magnetic microbeads /  10 CD4pos cells 
(Miltenyi Biotec, Bergisch Gladbach, Germany). HLA typing was 
performed by serological and DNA based techniques according to 
international (ASHI/EFI) standards [37].
CD4posCD25high Treg expansion
Cell cultures were performed in 96-well round bottom plates 
with culture medium consisting of RPMI 1640 supplemented with 
pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 mg/ 
ml), and 10% human pooled serum (HPS), in a 37oC, 95% 
humidity, 5% CO 2 incubator.
To optimize Treg expansion conditions, the mode and strength of 
stimulation, exogenous cytokine concentration, and expansion cycle 
length were varied in early experiments, as reported in the Results 
section. For assessment of cell division using CFSE, 1-5 x106 cells 
were labeled with 0.5 mM CFDA-SE (Molecular Probes) prior to 
stimulation. The final expansion protocols are described below.
For primary and secondary cycle alloantigen-specific expansion, 
2.5x104 T cells were cultured with 105 irradiated (30 Gy) HLA 
mismatched allogeneic PBMC (target alloantigen, ratio al- 
loPBMC:Treg = 4:1).
For first cycle polyclonal expansion, 2.5 x104 T cells were 
cultured with 1.25 x104 anti-CD3+ anti-CD28 coated microbeads 
(Dynal Biotech). For secondary cycle polyclonal expansion, 
2.5x104 Treg were cultured with 5 mg/ml platebound anti-CD3 
(UCHT1, BD Biosciences, 4 hours in PBS in incubator) plus
1 mg/ml soluble anti-CD28 (CD28.2, BD Biosciences).
Exogenous rhIL-2 (25 U/ml, Chiron, Amsterdam, the Nether­
lands) and rhIL-15 (10 ng/ml BioSource International, Camarillo, 
CA) were added to all expansion cultures. Wells were split and fresh 
medium containing cytokines was added every 3 days. After 10 days, 
the cells were harvested, washed and rested for 2 days in 5% HPS 
culture medium with 5 ng/ml rhIL-15 before analysis or further 
expansion. In all experiments, Tconv were included as control.
Flow cytometry
The phenotype of cells was analyzed by five-color flow cytometry 
(FC500, Beckman Coulter, Fullerton, CA). For cell surface staining, 
the following conjugated mAbs were used: CD25(M-A251)-PE, 
CD70(Ki-24)-PE, CD127(hIL-7R-M21)-AlexaFluor647 (BD Biosci­
ences), CD27(M-T271)-FITC (Dako), CD4-(SFCI12T4D11)-PCy7
Figure 9. Proliferative capacity o f expand ed  Treg. Treg and Tconv were expanded according the schedule in Figure 1 and rested for two days. 
Proliferative capacity of expanded cells upon restimulation with target alloantigen (same as used for expansion) was determined in the absence 
(black bars) or presence (grey bars) of IL-2. Proliferation was determined by measuring [3H]Thymidine incorporation at day 3. Results are expressed as 
percentage of [3H]Thymidine incorporation +SD. Data are representative of four independent experiments. 
doi:10.1371/journal.pone.0002233.g009
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Figure 10. Suppressive capacity o f expand ed  Treg in [3H]Thymidine incorporation suppression  assays. Treg and Tconv were expanded 
according the schedule in Figure 1 and rested for two days. (A) Suppressive capacity of Treg in target alloantigen and third party alloantigen 
responses as determined in a MLR co-culture using [3H]Thymidine incorporation. Autologous naive CD4posCD25neg Tresp cells were stimulated with 
target alloantigen (same as used for expansion) or third party HLA mismatched gamma irradiated allogeneic PBMC. Expanded Treg (black lines) or 
Tconv (grey lines) were added into these cultures at indicated Tresp:Treg/Tconv ratios. Proliferation was determined by measuring [3H]Thymidine 
incorporation at day 5. Results are expressed as percentage of [3H]Thymidine incorporation +SD, indexed to [3H]Thymidine incorporation of naive 
Tresp and antigen only. Data are representative of seven independent experiments. (B) Suppressive capacity of Treg in target alloantigen and third 
party alloantigen responses as determined in a MLR co-culture using CFSE dilution. CFSE labeled Autologous naive CD4posCD25neg Tresp cells were 
stimulated with PKH26 labeled target alloantigen (same as used for expansion) or PKH26 labeled third party HLA mismatched gamma irradiated 
allogeneic PBMC. Expanded Treg (black lines) or Tconv (grey lines) were added into these cultures at indicated Tresp:Treg/Tconv ratios. Proliferation 
was determined by measuring CFSE dilution of Tresp at day 5. Results are expressed as percentage of proliferating cells, indexed to percentages of 
proliferating cells in cultures of naive Tresp and antigen only. Data are representative of three independent experiments. 
doi:10.1371/journal.pone.0002233.g010
and CD62L(DREG56)-ECD (Beckman Coulter). To stain apoptotic 
cells, 7-amino-actinomycin-D (7AAD, Sigma-Aldrich, Zwijndrecht, 
the Netherlands) was added to cells prior to acquisition. For 
intracellular staining, Fix and Fix/Perm buffer (eBioscience, San 
Diego, CA) were used according to the manufacturer’s instructions 
in combination with FoxP3(259D/C7)-AlexaFluor647 or Bcl-2(100)- 
PE (BD Biosciences). Isotype controls were used for gate settings. In 
some experiments, cell were counted by flowcytometry using Flow- 
Count fluorospheres (Beckman Coulter).
Stimulation assay to analyze T cell anergy
T cell anergy was examined in (re-)stimulation assays. 2.5 x104 
cells were stimulated with 105 irradiated allogeneic stimulator 
PBMC in the presence or absence of IL-2 (12.5 U/ml). Classically, 
T cell anergy is defined as a low proliferative capacity upon 
stimulation with antigen only, which can be reversed by addition 
of exogenous IL-2. Proliferation was measured at indicated time­
points by determination of [3H]Thymidine incorporation as 
described above. Tests were set up in triplicate; results are 
expressed as mean+SD counts per 5 minutes.
Co-culture suppression assay
Suppressive capacity of Treg was studied in mixed lymphocyte 
reaction (MLR) co-culture suppression assays. Proliferation was 
determined by either [3H]Thymidine incorporation or CFSE 
dilution assays.
For assessment of cell division using [3H]Thymidine, 5x104 
naive autologous CD4posCD25neg T responder cells were
stimulated with 105 irradiated allogeneic stimulator PBMC (either 
target PBMC or HLA mismatched third party PBMC). Treg or 
Tconv were titrated into the cultures. Proliferation was measured 
at day 5. To this end, 0.5 mCi [3H]Thymidine (Amersham 
Biosciences, Piscataway, NJ) was added to each well. After
8 hours, [3H]Thymidine incorporation was measured using a 
beta-plate counter (Packard, Canberra, Australia). Tests were set 
up in triplicate; [ H]Thymidine incorporation were expressed as 
mean+SD counts per 5 minutes.
For assessment of cell division using CFSE dilution, naïve 
autologous 5-10x106 CD4posCD25neg T responder cells were 
labeled with 1 mM CFDA-SE (Molecular Probes) prior to 
stimulation, and allogeneic stimulator PBMC were labeled with
2 mM PKH26 (Sigma-Aldrich). 2.5 x104 CFSEpos T responder 
cells were stimulated with 105 PKH26pos irradiated allogeneic 
stimulator PBMC (either target PBMC or HLA mismatched third 
party PBMC). Unlabeled Treg or Tconv were titrated into the 
cultures. At day 5, 7-amino-actinomycin-D (7AAD, Sigma- 
Aldrich) was added to the samples. Tresp division was analyzed 
by flow cytometry (FC500, Beckman Coulter, Fullerton, CA), 
excluding 7AADpos cells, PKH26pos stimulator cells and CFSEneg 
Treg or Tconv and expressed as percentage dividing cells.
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